CLINICAL_TRIALS ClinicalTrials.gov record update

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03953898
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:56.887787+00:00
Published At: 2025-03-30T00:00:00+00:00
Record Updated At: 2026-04-13
Results Posted At: 2025-03-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Recurrent Acute Myeloid Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory Myelodysplastic Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-13"
protocolSection.identificationModule.nctId: "NCT03953898"
protocolSection.identificationModule.officialTitle: "The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-03-30"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.